Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study

BACKGROUND: Larotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This open-label, phase 1b study is aimed to evaluate the efficacy, safety of larotinib in patients with advanced esophageal squamous cell carcinoma (ESCC) with EGFR overexpression or am...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Rongrui, Liu, Lianke, Zhao, Chuanhua, Bai, Yuxian, Zheng, Yulong, Zhang, Shu, Li, Ning, Yang, Jianwei, Fan, Qingxia, Wang, Xiuwen, Zeng, Shan, Zhang, Yingjun, Zhang, Weihong, Zhuang, Yulei, Kang, Ning, Jiang, Yingzhi, Sun, Hongmei, Xu, Jianming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540164/
https://www.ncbi.nlm.nih.gov/pubmed/34688250
http://dx.doi.org/10.1186/s12876-021-01982-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8540164/
https://www.ncbi.nlm.nih.gov/pubmed/34688250
http://dx.doi.org/10.1186/s12876-021-01982-4

Ejemplares similares